Recent Advances in Genetic Predisposition to Primary Testicular Tumors

CHEK2 becomes the first moderate-penetrance predisposition gene identified for testicular germ cell tumors, alongside growing ties to inherited cancer syndromes

Journal: Seminars in Diagnostic Pathology | Published: 2026-05-06 | Type: Review | PMID: 42151003 Authors: Stephanie E. Siegmund (Department of Pathology, Brigham and Women's Hospital / Harvard Medical School, Boston, MA) Funding/COI: Funding not listed. Author declares no conflicts of interest.

Summary

Testicular germ cell tumors (GCTs) — roughly 95% of all primary testicular neoplasms — follow a polygenic inheritance model where no single gene dominates risk; hundreds of common low-penetrance alleles act in aggregate. The headline advancement in this review is the identification of pathogenic CHEK2 variants as the first moderate-penetrance gene associated with GCTs, a meaningful step up from the low-effect-size variants that GWAS has been generating for years. For rarer sex cord stromal tumors, the review also consolidates evidence linking them to established monogenic syndromes including Carney Complex, Peutz-Jeghers Syndrome, and HLRCC.

Claims

• Approximately 95% of primary testicular neoplasms are GCTs arising from germ cell neoplasia in situ (GCNIS)
• Risk for GCNIS-derived GCTs is polygenic — cumulative burden of many common, low-penetrance alleles, with susceptibility loci in pathways governing germ cell development, telomere maintenance, and DNA damage repair
• CHEK2 pathogenic variants are identified as the first moderate-penetrance predisposition gene for GCTs — prior candidates were all low-penetrance
• Sex cord stromal tumors are linked to Carney Complex (PRKAR1A), Peutz-Jeghers Syndrome (STK11), and HLRCC (FH) — established associations
• Newer associations with Familial Adenomatous Polyposis Syndrome (APC) and DICER1-Syndrome have been described but the author explicitly flags these as requiring further confirmation

Study Quality

This is a narrative review by a single author at a single institution — which is the appropriate format for synthesizing a field's advances, but carries the inherent limitations of that format. Narrative reviews are not systematic: the author selects which literature to include, and there is no registered protocol, no PRISMA flow diagram, no formal assessment of the quality or risk of bias in the primary studies being summarized. No sample sizes, effect sizes, or confidence intervals from the underlying GWAS or clinical studies are reproduced in the abstract, making it impossible to gauge the strength of any individual association from this paper alone.

The CHEK2 claim is the most significant and clinically forward-looking point in the abstract, but the review does not quantify what "moderate penetrance" means here — what relative risk, in how many cases, from which studies. That figure matters enormously for how actionable this finding is in clinical genetics practice.

Red Flags

• Narrative review format — susceptible to selection bias and cannot substitute for a systematic review on any specific claim
• No funding source disclosed, which is fine for a review but worth noting given that knowledge gaps in this area have commercial implications for genetic testing panels
• No quantitative effect sizes or confidence intervals reported for the CHEK2 association or any GWAS findings in the abstract
• APC and DICER1-Syndrome associations flagged by the author as unconfirmed — these should not be cited as established without the primary data
• Single-author review limits diversity of perspective when synthesizing a contested or emerging evidence base

Strengths

• Covers a genuinely underserved topic — testicular cancer genetics lacks the attention prostate and kidney cancer receive
• Distinguishes clearly between GCNIS-derived (polygenic) and GCNIS-independent (monogenic) tumor subtypes, which is the right conceptual frame
• Author explicitly flags unconfirmed associations rather than presenting them as settled, which reflects appropriate epistemic discipline
• Institutional affiliation (BWH/Harvard Pathology) provides credibility for a solo review
• CHEK2 identification is a real advance worth flagging — this gene is already on standard hereditary cancer panels for breast and colorectal cancer, so clinical uptake could follow quickly

Verdict

For anyone tracking testicular cancer genetics, this review is worth reading as a field map, not as primary evidence. The CHEK2 finding — the first moderate-penetrance gene for GCTs — is the single most clinically significant point, but you would need to go back to the primary CHEK2 papers to know what "moderate" actually means numerically. The review is honest about what's unconfirmed, which earns it points. As a narrative review without systematic methodology, it is not citable as evidence for any specific association — treat it as a curated reading list for a fast-moving area.